NEW YORK (AdAge.com) -- Eli Lilly and Co. has become the latest pharmaceutical company to run afoul of the Food and Drug Administration,
FDA ORDERS PFIZER'S BEXTRA WITHDRAWN
Cites 'Unfavorable' Risk vs. Benefits
FDA ORDERS ASTRAZENECA CRESTOR ADS PULLED
Cites 'Misleading Claims' in 'Clearly the Best' Ad Series
FDA ASKED PFIZER TO HALT CELEBREX ADS
No Indication How Long Suspension Will Last
PFIZER TO PULL CELEBREX CONSUMER ADVERTISING
But Says It Does Not Intend to Withdraw Drug From Market
MERCK PULLS $2.5 BILLION DRUG VIOXX OFF MARKET
$78 Million Advertising Account Is With DDB, FCB
The pharmaceutical company has been told to immediately pull its ad for the prescription medication for attention deficit hyperactivity disorder, or ADHD.
Lilly will comply
An Eli Lilly spokeswoman said the company will comply with the FDA's request, although it does not believe the ad to be misleading.
In a letter dated June 14 and released June 16, the FDA's Division of Drug Marketing, Advertising and Communications advised the company that the 60-second spot, entitled "Videogame," is false or misleading. The federal agency said the TV commercial "inadequately communicates the indication for Strattera and minimizes the risks associated with Strattera."
Foote Cone & Belding
The ad was created by Interpubilc Group of Cos.' Foote Cone & Belding
Eli Lilly has until June 28 to respond.
CORRECTION: An earlier version of this story incorrectly reported that the Division of Drug Marketing, Advertising and Communications said the commercial suggests a broader indication for the drug by promoting it for a similar affliction, attention-deficit disorder, or ADD.